期刊
BRITISH JOURNAL OF CANCER
卷 -, 期 -, 页码 -出版社
SPRINGERNATURE
DOI: 10.1038/s41416-023-02361-4
关键词
-
类别
Immune checkpoint therapies can enhance the function of anti-tumour T cells and improve outcomes in cancer patients. However, some patients are refractory to this therapy due to "cold" tumours that do not allow T cell generation or the infiltration of existing anti-tumour T cells. This review explores the mechanisms by which cancer cells induce T cell "desertification" and "exclusion" in these refractory tumours, and highlights the importance of developing immunotherapies that restore T cell generation and tumour trafficking.
Immune checkpoint therapies (ICT) can reinvigorate the effector functions of anti-tumour T cells, improving cancer patient outcomes. Anti-tumour T cells are initially formed during their first contact (priming) with tumour antigens by antigen-presenting cells (APCs). Unfortunately, many patients are refractory to ICT because their tumours are considered to be 'cold' tumours-i.e., they do not allow the generation of T cells (so-called 'desert' tumours) or the infiltration of existing anti-tumour T cells (T-cell-excluded tumours). Desert tumours disturb antigen processing and priming of T cells by targeting APCs with suppressive tumour factors derived from their genetic instabilities. In contrast, T-cell-excluded tumours are characterised by blocking effective anti-tumour T lymphocytes infiltrating cancer masses by obstacles, such as fibrosis and tumour-cell-induced immunosuppression. This review delves into critical mechanisms by which cancer cells induce T-cell 'desertification' and 'exclusion' in ICT refractory tumours. Filling the gaps in our knowledge regarding these pro-tumoral mechanisms will aid researchers in developing novel class immunotherapies that aim at restoring T-cell generation with more efficient priming by APCs and leukocyte tumour trafficking. Such developments are expected to unleash the clinical benefit of ICT in refractory patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据